EL7.AI
StocksHigh ImpactUpdated•Originally published 23 February 2026•Updated 23 February 2026•
1 min read

Gilead Sciences to Acquire Arcellx for $7.8 Billion in Major Biotech Deal

Key Facts

1Gilead Sciences agreed to buy Arcellx for $115 per share in cash.
2The deal includes an additional $5 per share Contingent Value Right (CVR) based on sales targets.
3Arcellx stock (ACLX) rose approximately 80% in premarket trade to align with the buyout price.

Gilead Sciences (GILD) has reached a definitive agreement to acquire cancer-therapy developer Arcellx (ACLX) in an all-cash transaction valued at approximately $7.8 billion. Under the terms of the deal, Gilead will pay $115 per share, plus a Contingent Value Right (CVR) worth an additional $5 per share contingent upon future sales targets. Following the announcement, Arcellx shares surged by approximately 80% in premarket trading, a significant gain that occurred despite a broader downturn in the equity markets. This strategic move is designed to significantly bolster Gilead's oncology pipeline and expand its footprint in advanced cancer treatments. Analysts expect this large-scale M&A activity to drive positive sentiment across the broader biotech sector and impact indices such as IBB and XBI, even amidst general market volatility.